Trade journal
Every trade since Sep 19, 2026, newest first, with the reasoning behind it.
Bought $1,000.00 of GOOGL at $341.24 (2.930488 shares)
It is just an absolutely crazy idea that Google has fallen so far behind OpenAI and Anthropic in LLM development. Since no frontier model has been dropped by Google for a while now, I am convinced that by the end of the year they will release Gemini 4 models that will take the lead on the leaderboards and drive the stock up to all-time highs. It already broke $400 a share once, so in my opinion, it will break that level again.
Bought $800.00 of META at $725.65 (1.102459 shares)
Their smart eyewear technology is becoming a leader in the space, and their AI models have made an unexpected comeback. I see a lot of upside for the company, but there is a major regulatory overhang that could impact their core social media business. We'll see this is definitely a calculated bet but overall, I believe the stock is undervalued. That said, we still need to observe whether smart eyewear truly becomes the next major consumer platform and whether Zuckerberg can earn lasting public trust.
Bought $1,200.00 of ETN at $429.63 (2.793101 shares)
Catalyst: Q2 sales rose 21%, organic sales 14%, Electrical-sector backlog 43% year over year, and management raised organic-growth guidance. Cash generation: trailing FCF $3.9B; Q2 free cash flow was up 22% year over year. Trend: +18.2% over 52 weeks and ~13.7% above the 200-day average
Bought $800.00 of TMO at $677.09 (1.181526 shares)
Medical research will accelerate significantly with AI, but at the end of the day, companies that possess the talent and infrastructure to execute clinical trials will capture massive upside. TMO has had strong financial years overall, and with more breakthroughs still ahead, I believe it remains undervalued.
Bought $800.00 of LLY at $1,194.22 (0.669893 shares)
Medical research will accelerate significantly with AI, but at the end of the day, companies that possess the talent and infrastructure to execute clinical trials will capture massive upside. Eli Lilly has had strong financial years overall, and with more breakthroughs still ahead, I believe it remains undervalued.
Bought $1,200.00 of AMZN at $246.53 (4.867561 shares)
Overall, it is a very healthy company that isn't directly exposed to in-house LLM development, but rather provides the underlying computing power to these companies. One thing I expect is that, since Amazon is also heavily invested in Anthropic and OpenAI ahead of next year's anticipated IPOs, they will be able to cash out big on those investments.
Bought $1,600.00 of GOOGL at $340.46 (4.699524 shares)
It is just an absolutely crazy idea that Google has fallen so far behind OpenAI and Anthropic in LLM development. Since no frontier model has been dropped by Google for a while now, I am convinced that by the end of the year they will release Gemini 4 models that will take the lead on the leaderboards and drive the stock up to all-time highs. It already broke $400 a share once, so in my opinion, it will break that level again.